文献速递肿瘤 PET/CT甲状腺核医学

胆囊收缩素-2受体PET/CT使用68Ga标记微胃泌素类似物DOTA-MGS5在甲状腺髓样癌患者中的初步临床经验

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer.
PubMed 文献 · J Nucl Med · 2023-01-19

六例晚期甲状腺髓样癌(MTC)患者接受68Ga-DOTA-MGS5 PET/CT以评估胆囊收缩素-2受体表达状态,回顾性分析注射后1小时和2小时的图像,共检出87个放射性摄取增高的恶性病灶(2个局部复发、8个淋巴结、27个肝、50个骨),病灶放射性蓄积在注射后2小时高于1小时(平均SUVmax 7.2 vs 6.0,平均SUVmean 4.4 vs 3.6)。

要点

  • 六例晚期MTC患者行68Ga-DOTA-MGS5 PET/CT,共检出87个恶性病灶。
  • 病灶摄取2小时高于1小时:平均SUVmax 7.2 vs 6.0,平均SUVmean 4.4 vs 3.6。
  • 初步结果示68Ga-DOTA-MGS5 PET/CT有检出晚期MTC局部复发和转移的潜力。

核心结论

  • 初步结果清楚显示68Ga-DOTA-MGS5 PET/CT在检出晚期MTC患者局部复发和转移方面具有潜力。

研究设计与样本

  • 六例晚期甲状腺髓样癌(MTC)患者接受68Ga-DOTA-MGS5 PET/CT,回顾性分析注射后1小时和2小时采集图像的生物分布与肿瘤靶向特性初步数据。

主要发现

  • 共检出87个放射性摄取增高、考虑为恶性的病灶,包括2个局部复发、8个淋巴结病灶、27个肝脏病灶和50个骨病灶。
  • 总体上病灶放射性蓄积在注射后2小时高于1小时:平均SUVmax 7.2 vs 6.0,平均SUVmean 4.4 vs 3.6。

局限性

  • 原文在标题和结论中均表述为「初步临床经验」和「初步结果」,样本为六例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PET/CT with the new 68Ga-labeled minigastrin analog DOTA-dGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (68Ga-DOTA-MGS5) was performed on patients with advanced medullary thyroid cancer (MTC) to evaluate cholecystokinin-2 receptor expression status. Methods: Six patients with advanced MTC underwent PET/CT with 68Ga-DOTA-MGS5. From the images acquired 1 and 2 h after injection, preliminary data on the biodistribution and tumor-targeting properties were evaluated in a retrospective analysis. Results: In total, 87 lesions with increased radiotracer uptake considered malignant were detected (2 local recurrences, 8 lymph node lesions, 27 liver lesions, and 50 bone lesions). In general, radiotracer accumulation in lesions was higher at 2 h than at 1 h after injection (mean SUVmax, 7.2 vs. 6.0, respectively; mean SUVmean, 4.4 vs. 3.6, respectively). Conclusion: The preliminary results clearly demonstrate the potential of 68Ga-DOTA-MGS5 PET/CT in detecting local recurrence and metastases in patients with advanced MTC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. von Guggenberg E, Uprimny C, Klinger M, et al. Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer. J Nucl Med. 2023. PMID: 36657979. doi:10.2967/jnumed.122.264977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。